CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 75,000 target
Drug / intervention
Cytology Specimen Collection Procedure +1 moreother
Likely dose
Not stated in record
Key inclusion· 7
  • ✓Enrollment within 6 months of initial disease presentation or within 6 months of refractory disease, progression, recurrence, second/secondary malignancy, or post-mortem
  • ✓All cancer cases with ICD-O histologic behavior code of 1 (borderline), 2 (carcinoma in situ), or 3 (malignant)
  • ✓All neoplastic lesions of the central nervous system regardless of behavior
  • ✓All neoplastic lesions of the kidney regardless of behavior
Key exclusion· 1
  • ✕Melanocytic tumors that are clearly benign nevi are excluded

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02402244
NCT02402244N/ARecruitingHigh Momentum
Long Recruiting
CompareCT.gov

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Children's Oncology Group·observational·Posted Mar 30, 2015·Updated May 5, 2026

In Brief

An observational study evaluating Cytology Specimen Collection Procedure and Medical Chart Review for Adrenal Gland Pheochromocytoma and 17 related conditions. Currently recruiting, targeting 75,000 participants across 278 sites in 6 countries.

Signals

Enrolling ahead of pace

Detailed Summary

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAdrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Kidney Neoplasm, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Desmoid Fibromatosis, Ganglioneuroma, Lymphoproliferative Disorder, Malignant Neoplasm, Malignant Solid Neoplasm, Melanocytic Neoplasm, Myeloproliferative Neoplasm, Neoplasm of Uncertain Malignant Potential, Neuroendocrine Neoplasm, Stromal Neoplasm
CountriesAustralia, Canada, New Zealand, Puerto Rico, Saudi Arabia, United States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ARecruiting
20152016201720182019202020212022202320242025202620272028202920302031
First PostedMar 30, 2015
Enrollment StartNov 3, 2015
Primary CompletionDec 31, 2030
TodayJul 2, 2026
Enrollment to primary: 15.2 yearsPosted 11.3 years agoPrimary completion in 4.5 years

Interventions

Cytology Specimen Collection Procedureother

Undergo cytology specimen collection

Medical Chart Reviewother

Undergo medical data review